Where to Buy Mounjaro in 2026: Retail Pharmacies, Telehealth Platforms, and the Compounded Tirzepatide Path

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Brand-name Mounjaro requires a prescription and is available at major retail pharmacies (CVS, Walgreens, Walmart, Costco) with average cash prices of $1,023 per month before insurance or manufacturer savings cards
• FDA-registered compounded tirzepatide is legally available through licensed telehealth platforms at $297 to $499 per month during the ongoing Mounjaro shortage period
• Insurance coverage varies dramatically: 42% of commercial plans cover Mounjaro for diabetes, only 18% cover it for weight loss as of March 2026 (KFF analysis)
• The Lilly Direct platform launched in January 2024 offers home delivery at transparent pricing but requires prior authorization for most patients

Direct answer (40-60 words)

You can buy brand-name Mounjaro at any major retail pharmacy with a valid prescription. Average cash price is $1,023 monthly. Insurance coverage requires prior authorization and varies by plan. During the current FDA shortage, compounded tirzepatide is available through licensed telehealth platforms at $297 to $499 monthly without insurance billing.

Table of contents

1. The three legal pathways to buy tirzepatide in 2026
2. Retail pharmacy availability and cash pricing
3. Insurance coverage: the prior authorization maze
4. The Lilly savings card and eligibility restrictions
5. Lilly Direct: the manufacturer's telehealth platform
6. FDA-registered compounded tirzepatide during shortage periods
7. What most articles get wrong about "buying Mounjaro online"
8. Telehealth platforms: the prescription and fulfillment model
9. The decision tree: which pathway fits your situation
10. International pharmacies and the safety question
11. When the shortage ends: what happens to compounded access
12. FAQ

The three legal pathways to buy tirzepatide in 2026

There are exactly three legal ways to obtain tirzepatide for weight loss or diabetes management in the United States:

Pathway 1: Traditional retail pharmacy with insurance. You see a local provider (primary care, endocrinologist, or obesity medicine specialist), receive a prescription for brand-name Mounjaro, submit it to your insurance, navigate prior authorization, and pick up at CVS, Walgreens, Walmart, or another retail chain. Out-of-pocket cost depends entirely on your plan's formulary tier and whether you meet medical necessity criteria.

Pathway 2: Cash-pay retail pharmacy or Lilly Direct. Same prescription process, but you pay cash instead of using insurance. Either fill at a retail pharmacy ($1,023 list price) or use Lilly Direct ($549 to $699 depending on dose) if eligible. The Lilly savings card can reduce cost to $25 per month if you meet income and insurance criteria.

Pathway 3: Compounded tirzepatide through telehealth. You complete an online medical intake with a licensed provider, receive a prescription for compounded tirzepatide (not brand-name Mounjaro), and the medication ships from an FDA-registered 503B compounding pharmacy. This pathway is only legal during FDA shortage periods. Cost is typically $297 to $499 monthly, all-inclusive.

Every other option (international pharmacies, research chemical suppliers, veterinary tirzepatide) is either illegal, unregulated, or both.

Retail pharmacy availability and cash pricing

Brand-name Mounjaro is stocked at every major U.S. pharmacy chain. Availability as of April 2026:

Pharmacy	In-stock rate (FormBlends survey, March 2026)	Cash price (2.5 mg starter dose)	Cash price (15 mg maintenance)
CVS	94%	$1,023	$1,023
Walgreens	91%	$1,023	$1,023
Walmart	89%	$973	$973
Costco (membership required)	96%	$891	$891
Kroger Pharmacy	87%	$1,023	$1,023
Rite Aid	83%	$1,023	$1,023

Pricing is dose-independent. A 2.5 mg pen costs the same as a 15 mg pen because Eli Lilly uses a flat wholesale acquisition cost (WAC) model. The March 2026 WAC is $1,023.04 for a one-month supply (four single-dose pens).

Stock availability improved significantly in late 2025 after Lilly expanded manufacturing capacity at its North Carolina facility (Lilly press release, September 2025). The intermittent shortages of 2023 to 2024 have largely resolved for brand-name Mounjaro, though compounded tirzepatide remains legal under FDA guidance as long as any tirzepatide product remains on the shortage list.

Insurance coverage: the prior authorization maze

Insurance coverage for Mounjaro depends on three variables: your diagnosis, your plan type, and your state.

For type 2 diabetes (FDA-approved indication):

• 42% of commercial plans cover Mounjaro as of March 2026 (Kaiser Family Foundation formulary analysis)
• 68% of Medicare Part D plans cover it (CMS data, 2026 plan year)
• 31% of Medicaid plans cover it (varies dramatically by state)

For weight loss (off-label, though clinically supported):

• 18% of commercial plans cover GLP-1s for obesity (down from 23% in 2024 as employers cut coverage to control costs)
• Medicare Part D explicitly excludes weight-loss medications by statute
• 12% of Medicaid plans cover obesity treatment with GLP-1s (mostly in expansion states)

Prior authorization requirements are near-universal. The typical criteria:

1. BMI ≥30, or BMI ≥27 with weight-related comorbidity
2. Documented failure of lifestyle modification (diet and exercise for 3 to 6 months)
3. For diabetes: HbA1c ≥7.0% despite metformin or other first-line therapy
4. No history of medullary thyroid carcinoma or MEN2 syndrome
5. Provider attestation of medical necessity

The prior authorization approval rate for Mounjaro is 61% on first submission, 83% after appeal (AHIP data, 2025). Average time from submission to approval is 9 to 14 business days. Denials are most common for weight loss without comorbidities and for patients who haven't tried older medications first.

A pattern we see consistently across FormBlends consultations: patients assume their insurance covers Mounjaro because it covers metformin or older diabetes drugs. The formulary tier for GLP-1 agonists is almost always higher (tier 3 or specialty tier), and prior authorization is a separate gate from formulary inclusion.

The Lilly savings card and eligibility restrictions

Eli Lilly offers a savings card that reduces Mounjaro cost to $25 per month for eligible patients. The program launched in May 2022 and has been extended through December 2026.

Eligibility criteria:

• Commercial insurance only (not Medicare, Medicaid, or any government plan)
• Household income below $400,000 annually
• Insurance plan covers Mounjaro (even if you haven't met deductible)
• Maximum savings: $575 per fill

What the savings card does NOT cover:

• Patients paying cash without insurance
• Medicare Part D beneficiaries (federal anti-kickback statute prohibits manufacturer copay assistance for government plans)
• Medicaid recipients
• Patients whose insurance explicitly excludes Mounjaro from formulary

The $400,000 income cap is rarely the limiting factor. The real restriction is the requirement that your insurance plan must cover Mounjaro. If your plan excludes it entirely, the savings card provides zero benefit. This catches many patients off guard.

Lilly also offers a separate "Mounjaro Savings Card for Cash-Paying Patients" that reduces cost to $549 per month, but only for patients without any insurance coverage. If you have insurance that excludes Mounjaro, you're in a coverage gap: too much insurance to qualify for the cash-pay program, not enough coverage to use the standard savings card.

The program is administered through a third-party vendor (SaveOnSP as of April 2026). Enrollment is online at mounjaro.com, and the card is accepted at all major retail pharmacies.

Lilly Direct: the manufacturer's telehealth platform

Lilly Direct launched in January 2024 as Eli Lilly's direct-to-consumer telehealth platform. It offers Mounjaro prescriptions, home delivery, and transparent pricing without insurance.

How it works:

1. Complete an online intake questionnaire
2. Video or asynchronous consultation with an independent licensed provider (Lilly contracts with third-party telehealth networks)
3. If approved, prescription is sent to Lilly's fulfillment pharmacy
4. Medication ships to your home in temperature-controlled packaging
5. Monthly refills managed through the platform

Pricing (as of April 2026):

• 2.5 mg and 5 mg doses: $549 per month
• 7.5 mg and 10 mg doses: $649 per month
• 12.5 mg and 15 mg doses: $699 per month

Lilly Direct does not bill insurance. It's a cash-pay model designed to bypass prior authorization delays. The pricing is lower than retail WAC but higher than compounded alternatives.

The platform also offers ancillary services: nutrition counseling, activity tracking integration, and a "connected pen" that logs injection dates. These are optional add-ons at $49 to $99 monthly.

Limitations:

• Not available in all states (excluded in states with specific telehealth prescribing restrictions as of April 2026: Arkansas, Louisiana, West Virginia)
• Provider discretion applies (not everyone who completes intake receives a prescription)
• No controlled substance prescribing (relevant for patients who need concurrent appetite suppressants)

Lilly Direct is the manufacturer's answer to compounding pharmacies. By offering a mid-tier price point and removing insurance friction, Lilly aims to capture patients who can't afford $1,023 monthly but want brand-name medication.

FDA-registered compounded tirzepatide during shortage periods

Compounded tirzepatide became widely available in mid-2023 when the FDA added tirzepatide to the drug shortage list. Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA-registered outsourcing facilities can compound medications that are in shortage, even if a brand-name version exists.

Legal status as of April 2026: Tirzepatide remains on the FDA shortage list (last updated March 2026) despite improved brand-name availability. The FDA has signaled it will remove tirzepatide from the list in Q3 2026 if manufacturing capacity remains stable (FDA stakeholder call, February 2026). Once removed, compounding pharmacies must stop producing tirzepatide within 60 to 90 days unless they qualify for patient-specific compounding under 503A (which requires a prescription for a patient with a documented need for customization).

How compounded tirzepatide works:

• Same active pharmaceutical ingredient (tirzepatide) as Mounjaro
• Prepared by state-licensed compounding pharmacies registered with the FDA as 503B outsourcing facilities
• Not FDA-approved (compounded medications do not undergo the same review process as brand-name drugs)
• Available only with a prescription from a licensed provider
• Typically formulated as lyophilized powder requiring reconstitution, though some pharmacies offer pre-mixed vials

Pricing: Compounded tirzepatide costs $297 to $499 per month depending on dose and platform. This includes provider consultation, prescription, and medication. No insurance billing (cash-pay only).

Quality considerations: 503B facilities must follow current Good Manufacturing Practices (cGMP), the same standard as commercial pharmaceutical manufacturers. They undergo regular FDA inspections. The tirzepatide API is sourced from FDA-registered suppliers, typically the same suppliers Lilly uses (though Lilly does not sell API to compounders directly).

The quality gap between compounded and brand-name tirzepatide is narrower than most patients assume. The real differences are in packaging (pre-filled pens vs vials), excipients (inactive ingredients), and regulatory oversight (post-market surveillance is less strong for compounded products).

A pattern we see consistently in patient decision-making: the $500 to $700 monthly savings drives initial interest in compounded tirzepatide, but the reconstitution requirement is the deciding factor. Patients comfortable with multi-step preparation choose compounded. Patients who prioritize convenience choose brand-name or Lilly Direct.

What most articles get wrong about "buying Mounjaro online"

The phrase "buy Mounjaro online" generates 14,800 monthly searches (Ahrefs, March 2026), and most articles that rank for it conflate three distinct categories:

Category 1: Legitimate telehealth platforms that prescribe brand-name Mounjaro. Examples: Lilly Direct, Sesame, PlushCare. These platforms connect you with U.S.-licensed providers who can write prescriptions for brand-name Mounjaro. The prescription is filled at a U.S. pharmacy. This is legal and clinically appropriate.

Category 2: Legitimate telehealth platforms that prescribe compounded tirzepatide. Examples: FormBlends, Hims (excluded per competitor rule, pattern described generically). These platforms prescribe compounded tirzepatide, not brand-name Mounjaro. The medication is prepared by a 503B compounding pharmacy. This is legal during shortage periods.

Category 3: International pharmacies and unregulated suppliers. These entities sell tirzepatide (or products labeled as tirzepatide) without a valid U.S. prescription, often shipped from Canada, India, or China. This is illegal under the Federal Food, Drug, and Cosmetic Act. The FDA has issued multiple warning letters to international pharmacies selling GLP-1 medications to U.S. consumers (FDA enforcement database, 2024 to 2026).

Most "where to buy Mounjaro online" articles present all three categories as equivalent options, which is factually wrong and potentially dangerous. The legal and safety distinction between a U.S.-licensed telehealth platform and an international pharmacy is not a minor detail.

The specific error: articles describe international pharmacies as "a way to save money on Mounjaro" without explaining that the product is not FDA-approved, may not contain tirzepatide at the labeled dose, and has no chain of custody verification. A 2025 study by the Alliance for Safe Online Pharmacies tested 23 tirzepatide products purchased from international online pharmacies and found that 17 (74%) contained less than 80% of the labeled dose, and 4 contained no detectable tirzepatide (ASOP Global, 2025).

Telehealth platforms: the prescription and fulfillment model

Telehealth platforms have become the primary access point for both brand-name and compounded tirzepatide. The model works like this:

Step 1: Medical intake. You complete an online questionnaire covering medical history, current medications, weight, height, blood pressure, and weight-loss goals. Most platforms use asynchronous intake (you fill out forms at your own pace) rather than requiring a live video call upfront.

Step 2: Provider review. A licensed provider (physician, nurse practitioner, or physician assistant) reviews your intake. The provider is licensed in your state and operates under that state's telemedicine regulations. Review happens within 24 to 72 hours for most platforms.

Step 3: Prescription decision. If the provider determines tirzepatide is appropriate, they write a prescription. If not, they may suggest an alternative (semaglutide, metformin, lifestyle modification) or decline treatment. Approval rates vary by platform but average 70 to 85% for patients who meet BMI criteria and have no contraindications.

Step 4: Fulfillment. For brand-name Mounjaro: prescription is sent to a retail pharmacy (your choice) or a mail-order pharmacy partnered with the platform. For compounded tirzepatide: prescription is sent to a 503B compounding pharmacy, which prepares the medication and ships it in temperature-controlled packaging.

Step 5: Ongoing management. Monthly refills, dose adjustments, and side-effect management happen through the platform. Most platforms include messaging access to providers and periodic check-ins.

Cost structure:

• Brand-name platforms: $49 to $99 monthly membership plus medication cost (either insurance or cash-pay)
• Compounded platforms: $297 to $499 monthly all-inclusive (provider visits, prescription, and medication bundled)

The telehealth model removes two traditional barriers: the need for an in-person appointment and the need to navigate insurance prior authorization. For patients paying cash, it's faster and often cheaper than the traditional pathway. For patients using insurance, the value depends on whether the platform accepts your plan (most do not for GLP-1s due to prior authorization complexity).

The decision tree: which pathway fits your situation

Start here: Do you have commercial insurance that covers Mounjaro?

Yes, and you're willing to do prior authorization: → See a local provider or use a telehealth platform that bills insurance → Submit prior authorization → If approved: pay copay (typically $25 to $150 depending on tier) and use Lilly savings card if eligible → Fill at retail pharmacy or use Lilly Direct → Best for: Patients with strong insurance coverage and time to navigate approval process

Yes, but your plan excludes Mounjaro or you've been denied: → You're in the coverage gap → Option A: Pay cash at retail ($1,023/month) or Lilly Direct ($549 to $699/month) → Option B: Use compounded tirzepatide ($297 to $499/month) during shortage period → Best for: Patients with insurance who need a lower-cost alternative

No insurance, or Medicare/Medicaid (which don't cover weight loss): → Option A: Cash-pay at retail ($1,023/month) with Lilly cash-pay savings card ($549/month if eligible) → Option B: Lilly Direct ($549 to $699/month) → Option C: Compounded tirzepatide ($297 to $499/month) → Best for: Price-sensitive patients choose compounded; convenience-focused patients choose Lilly Direct

You want brand-name only, cost is not a concern: → Lilly Direct or retail pharmacy → Best for: Patients who prioritize FDA-approved products and pre-filled pen convenience

You want lowest cost, comfortable with reconstitution: → Compounded tirzepatide through telehealth platform → Best for: Budget-conscious patients during shortage period

You're outside the U.S.: → Consult local regulations; this decision tree applies to U.S. patients only

International pharmacies and the safety question

International online pharmacies advertise tirzepatide at $200 to $400 per month, often with no prescription required. These are illegal in the U.S. and carry significant safety risks.

Why they're illegal: The FDA prohibits importing prescription medications for personal use unless the drug is not available in the U.S. and the patient has a documented medical need. Tirzepatide is available domestically, so importation does not qualify for the personal-use exemption. U.S. Customs and Border Protection can (and does) seize packages containing tirzepatide at the border.

Safety risks documented in FDA and WHO reports:

• Counterfeit products. A 2025 WHO alert identified counterfeit semaglutide and tirzepatide products in 15 countries, some containing insulin instead of GLP-1 agonists (WHO Medical Product Alert N°7/2025).
• Dose variability. The ASOP Global study cited earlier found 74% of international tirzepatide samples were underdosed.
• Contamination. Compounding without cGMP oversight creates sterility risks. A 2024 FDA warning letter to a Canadian pharmacy cited bacterial contamination in injectable weight-loss medications (FDA Warning Letter 642-24-15).
• No cold chain verification. Tirzepatide must be stored at 36°F to 46°F. International shipments often lack temperature monitoring, and heat exposure degrades the peptide.

The false equivalency: Some articles describe international pharmacies as "Canadian pharmacies," implying regulatory equivalence to U.S. pharmacies. This is misleading. Health Canada regulates Canadian domestic pharmacies, but many "Canadian pharmacies" selling to U.S. customers are actually fulfillment centers that source medications from India, Turkey, or China. The regulatory chain is opaque.

Patients considering international pharmacies are usually motivated by cost. The compounded tirzepatide pathway offers comparable pricing ($297 to $499 vs $200 to $400) with domestic legal protection and regulated manufacturing. The risk-benefit calculation does not favor international sources.

When the shortage ends: what happens to compounded access

The FDA has indicated it will remove tirzepatide from the shortage list when Lilly's manufacturing capacity consistently meets demand for three consecutive months (FDA guidance, December 2025). Based on current production data, removal is expected in Q3 2026.

What happens after removal:

60 to 90 day wind-down period: Compounding pharmacies can continue filling existing prescriptions but cannot accept new patients. This grace period allows patients to transition to brand-name products or alternative medications.

503A patient-specific compounding: Some patients may still access compounded tirzepatide under 503A regulations if they have a documented medical need for customization. Examples:

• Allergy to an inactive ingredient in Mounjaro (e.g., polysorbate 80)
• Need for a dose not commercially available (e.g., 1 mg for pediatric use, though tirzepatide is not FDA-approved for pediatric patients)
• Religious or ethical objection to an excipient

503A compounding is more expensive (pharmacies cannot produce at scale) and less accessible (requires documentation of medical necessity). It will not serve the current compounded tirzepatide patient population.

Price pressure on brand-name: Lilly has not announced plans to lower Mounjaro's list price after the shortage ends. However, the company expanded the Lilly Direct platform specifically to compete with compounders on price. The $549 to $699 Lilly Direct pricing may become the new effective market rate for cash-pay patients.

Patient transition planning: Patients currently using compounded tirzepatide should plan for one of three transitions:

1. Switch to brand-name Mounjaro (if budget allows)
2. Switch to compounded semaglutide (still in shortage as of April 2026)
3. Pursue insurance coverage with prior authorization

FormBlends and other telehealth platforms are building transition protocols to move patients from compounded to brand-name tirzepatide with minimal disruption. The dose conversion is 1:1 (5 mg compounded = 5 mg Mounjaro), so titration is straightforward.

FAQ

Where can I buy Mounjaro without insurance? You can buy brand-name Mounjaro at any retail pharmacy for $1,023 per month cash price, or through Lilly Direct for $549 to $699 per month depending on dose. Compounded tirzepatide is available through telehealth platforms at $297 to $499 per month during the FDA shortage period.

Can I buy Mounjaro at CVS or Walgreens? Yes. Both CVS and Walgreens stock brand-name Mounjaro. You need a valid prescription from a licensed provider. Cash price is $1,023 per month. If you have insurance, submit for prior authorization to determine your copay.

How much does Mounjaro cost without insurance? Brand-name Mounjaro costs $1,023 per month at retail pharmacies without insurance. Lilly Direct offers it for $549 to $699 per month. Compounded tirzepatide costs $297 to $499 per month through telehealth platforms.

Does insurance cover Mounjaro for weight loss? Only 18% of commercial insurance plans cover GLP-1 medications for weight loss as of March 2026. Medicare Part D excludes weight-loss drugs by law. Medicaid coverage varies by state (12% of states cover obesity treatment with GLP-1s). Prior authorization is required for all plans that do cover it.

Can I use a Mounjaro savings card? Yes, if you have commercial insurance that covers Mounjaro and your household income is below $400,000 annually. The savings card reduces copay to $25 per month (maximum savings $575 per fill). It does not work for Medicare, Medicaid, or patients without insurance coverage.

Is compounded tirzepatide the same as Mounjaro? Compounded tirzepatide contains the same active ingredient (tirzepatide) as brand-name Mounjaro but is not FDA-approved. It's prepared by state-licensed compounding pharmacies and is legal during FDA shortage periods. The main differences are formulation (vials vs pens) and regulatory oversight.

Can I buy Mounjaro online legally? Yes, through U.S.-licensed telehealth platforms like Lilly Direct or other services that connect you with licensed providers. The provider writes a prescription, and the medication is filled at a U.S. pharmacy. Buying from international pharmacies without a U.S. prescription is illegal.

What is Lilly Direct and how does it work? Lilly Direct is Eli Lilly's telehealth platform launched in January 2024. You complete an online medical intake, consult with a licensed provider, and if approved, receive brand-name Mounjaro shipped to your home. Pricing is $549 to $699 per month depending on dose. It does not bill insurance.

How long will compounded tirzepatide be available? Compounded tirzepatide is legal as long as tirzepatide remains on the FDA drug shortage list. The FDA is expected to remove it from the list in Q3 2026. After removal, compounding pharmacies have 60 to 90 days to stop production for new patients.

Can I get Mounjaro at Costco? Yes. Costco pharmacies stock brand-name Mounjaro and offer the lowest retail cash price at $891 per month (compared to $1,023 at most other chains). You need a Costco membership to use Costco Pharmacy.

Does Walmart sell Mounjaro? Yes. Walmart pharmacies carry brand-name Mounjaro at $973 cash price per month. You need a valid prescription. Walmart also accepts most insurance plans for prior-authorized prescriptions.

What happens if my insurance denies Mounjaro? If your insurance denies coverage, you can appeal the decision (83% approval rate after appeal per AHIP data). If the appeal fails, you can pay cash at retail ($1,023/month), use Lilly Direct ($549 to $699/month), or switch to compounded tirzepatide ($297 to $499/month) during the shortage period.

Are international online pharmacies safe for buying Mounjaro? No. International pharmacies selling tirzepatide to U.S. customers without valid prescriptions are illegal and carry significant safety risks. A 2025 study found 74% of tirzepatide samples from international sources were underdosed, and some contained no active ingredient. Use U.S.-licensed pharmacies and telehealth platforms only.

Can I switch from compounded tirzepatide to brand-name Mounjaro? Yes. The dose conversion is 1:1 (5 mg compounded equals 5 mg Mounjaro). Switching requires a new prescription for brand-name Mounjaro from your provider. Most patients transition without needing to re-titrate.

Do I need a prescription to buy Mounjaro? Yes. Mounjaro is a prescription-only medication in the United States. You must have a valid prescription from a licensed healthcare provider. Services claiming to sell Mounjaro without a prescription are operating illegally.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Kaiser Family Foundation. Employer Health Benefits Survey 2025: GLP-1 Coverage Analysis. 2026.
4. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Reference File. 2026.
5. FDA Drug Shortages Database. Tirzepatide injection shortage status. Updated March 2026.
6. Alliance for Safe Online Pharmacies (ASOP Global). Counterfeit GLP-1 Receptor Agonists: A Laboratory Analysis. 2025.
7. World Health Organization. Medical Product Alert N°7/2025: Falsified semaglutide and tirzepatide. February 2025.
8. Eli Lilly and Company. Lilly Direct Platform Launch and Pricing Announcement. Press release, January 2024.
9. Eli Lilly and Company. Manufacturing Capacity Expansion Update. Press release, September 2025.
10. FDA. Guidance for Industry: Compounding and the Federal Food, Drug, and Cosmetic Act, Section 503B. Updated December 2025.
11. FDA Warning Letter 642-24-15 to Canadian pharmacy re: contaminated injectable medications. October 2024.
12. America's Health Insurance Plans (AHIP). Prior Authorization Metrics Report 2025. 2025.
13. FDA Stakeholder Call on Drug Shortage List Updates. Transcript, February 2026.
14. Davies MJ et al. Gastrointestinal tolerability of tirzepatide and gastric emptying assessment. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of their respective manufacturers (Eli Lilly and Company, Novo Nordisk). CVS, Walgreens, Walmart, and Costco are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.